Isivivinyo se-ARROW, I-Genentech, I-NSCLC, i-pralsetinib
I-Pralsetinib igunyazwe yi-FDA yomdlavuza wamaphaphu ongewona omncane nge-RET fusion gene
Agasti 2023: I-Pralsetinib (Gavreto, Genentech, Inc.) yanikezwa imvume evamile yi-Food and Drug Administration ezigulini ezikhulile ezinomdlavuza we-RET fusion-positive non-small cell lung cancer (NSCLC), njengoba kunqunywe i-FDA.
I-CD20, Columbi, I-DLBCL, I-Genentech
I-Glofitamab-gxbm igunyazwe yi-FDA kuma-B-cell lymphomas akhethiwe abuyele emuva noma aphikisayo.
Julayi 2023: Ukuphathwa Kwezokudla Nezidakamizwa kunikeze imvume esheshisiwe ku-glofitamab-gxbm (Columvi, Genentech, Inc.) yokusabalalisa kabusha i-B-cell lymphoma enkulu, engashiwongo ngenye indlela (i-DLBCL, i-NOS) noma i-B-cell ly enkulu.
I-Genentech, Lunsumio, mosunetuzumab-axgb, i-reflexory follicular lymphoma
I-Mosunetuzumab-axgb inikezwa ukugunyazwa okusheshisiwe kwe-lymphoma ye-follicular ebuyele emuva noma ephikisayo.
Jan 2023: I-Mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), i-CD20-directed bispecific CD3 T-cell engageer yeziguli ezikhulile ezine-lymphoma ephindaphindayo noma e-refractory follicular lymphoma (FL) elandela imizuliswano emibili noma ngaphezulu ye-systemic therapy, iyaphinda.
i-alveolar soft part sarcoma, I-Atezolizumab, uhlelo oluyisisekelo senzwa, I-Genentech, I-Tecentriq
I-Atezolizumab igunyazwe yi-FDA ye-alveolar soft tissue sarcoma
Dec 2022: I-Atezolizumab (Tecentriq, Genentech, Inc.) igunyazwe yi-Food and Drug Administration (FDA) yeziguli zabantu abadala kanye nezingane ezinengxenye ethambile ye-alveolar engabonakali noma ene-metastatic esineminyaka engu-2 ubudala.
I-Burkitt lymphoma, I-Burkitt-like lymphoma, I-DLBCL, I-Genentech, I-Rituxan, I-Rituximab
I-Rituximab plus chemotherapy igunyazwe yi-FDA ngezinkomba zomdlavuza wezingane
Mashi 2022: I-Food and Drug Administration igunyaze i-rituximab (Rituxan, Genentech, Inc.) ngokuhlanganyela ne-chemotherapy ye-CD20-positive diffuse big-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma.
I-Atezolizumab, I-Genentech, I-NSCLC, I-Tecentriq, Izinhlelo zeVentana Medical, I-VENTANA PD-L1
I-Atezolizumab igunyazwe yi-FDA njengokwelashwa kwe-adjuvant kumdlavuza wamaphaphu ongewona omncane
Nov 2021: I-Food and Drug Administration igunyaze i-atezolizumab (Tecentriq, Genentech, Inc.) yokwelashwa kwe-adjuvant ezigulini ezinomdlavuza wamaphaphu we-cell ongewona omncane wesigaba II kuya ku-III (NSCLC) izimila zazo eziqukethe i-PD-L1 inkulumo.